ERBB2 and breast cancer: In addition, human breast cancer cells overexpressing HER2 or acquiring resistance to the oestrogen receptor (ER) antagonist, fulvestrant (Faslodex, ICI 182,780), have been reported to be particularly sensitive to gefitinib (McClelland et al, 2001; Moulder et al, 2001).